Processa Pharmaceuticals, Inc. PCSA
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is an immunology/inflammation drug developer. Its lead program, VT-7208, is in Phase 1 for Food allergy, chronic spontaneous urticaria, relapsing multiple sclerosis.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VT-7208 (BTK inhibitor) | Food allergy / CSU / RMS | small molecule | Phase 2 PoC food allergy data 2027-H2; CSU 2028-H1; RMS 2028-H2 |
| PCS11T (NGC-Iri) | Solid tumors | small molecule | — |
Recent results and decisions
- Nov 5, 2026accepted FDA cleared the IND application for the planned Phase 2 clinical trial of VT-7208 in chronic spontaneous urticaria.
The FDA has cleared the IND application for our planned Phase 2 clinical trial of VT-7208 in CSU, allowing us to move forward with the study in this large patient population.
Filing - Oct 29, 2026accepted FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria.
The FDA has cleared the IND application for VT-7208 in CSU, enabling Processa to advance the program into a Phase 2 study in adults with moderate-to-severe disease.
Filing - Oct 29, 2026started Processa plans to initiate Phase 2 study enrolling approximately 120 adults with CSU inadequately controlled by H1 antihistamines.
The planned multicenter, randomized, double-blind, placebo-controlled study is expected to enroll approximately 120 adults whose disease is not adequately controlled with H1 antihistamines.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.